revenue in our network segment were $ 440 million , flat versus last year and down 3 % on an organic basis .
for the second quarter , we 're establishing adjusted deps guidance to be between $ 3.61 and $ 3.65 and expect second quarter organic revenue growth to be in line with the full - year organic growth rate .
the 6 % to 7 % organic growth is against a 1 % organic decline in 2020 .
ebitda margins expanded nicely and free cash flow grew 54 % to $ 543 million , which enabled us to continue our rapid deleveraging in the quarter .
bill has been a roper director since 1997 and has reached our mandatory board retirement age .
across this segment , we saw organic recurring revenue , which is about 75 % of the revenue for this segment , increase approximately 6 % .
now , please turn to page 14 , where i 'll highlight our increased guidance for 2021 .
turning to page 15 and our closing summary .
clinisys has approximately 85 % market share in the uk and is now recognized as one of four critical it vendors for the entire national health service .
our results were enhanced a bit by approximately $ 40 million of accelerated payments that were the result of wins at our uk - based clinisys laboratory software business .
ebitda margin increased 220 basis points to 36.7 % , on really great incrementals across the portfolio .
our non -software businesses in this segment were down 13 % for the quarter ; a touch better than we anticipated .
adjusted deps was $ 3.60 , 18 % above prior year .
